Prostate tumor-overexpressed gene 1 protein (PTOV1)

**Prostate tumor-overexpressed gene 1 protein (PTOV1)** is an adaptor protein originally identified as overexpressed in prostate cancer and other tumors, encoded by the *PTOV1* gene on chromosome 19q13.3[1]. It contains two tandem domains (A and B), each with nuclear localization sequences, and an N-terminal extended AT-hook motif, conferring nucleic acid binding ability (with higher affinity for RNA than DNA)[1][2]. PTOV1 acts as a transcriptional and post-transcriptional regulator by interacting with transcriptional repressors/activators, histone modifying enzymes (including HDACs and NCoR), and ribonucleoprotein complexes. It promotes cancer cell proliferation, survival, and motility, and is associated with the acquisition of cancer stem cell-like features and resistance to therapy[1][2]. PTOV1 does not interact with the Mediator complex (unlike its paralog MED25), but it regulates gene expression by modulating the localization or function of various factors, such as RACK1, HDAC1, CBP, and others. Overexpression of PTOV1 correlates with poor prognosis in prostate and other cancers, making it a candidate biomarker and potential therapeutic target, though specific PTOV1-targeting drugs have not yet been reported[1][2][3].

Other names

Prostate tumor-overexpressed gene 1 proteinPTOV1ACID2PP642UNQ6127/PRO20092PTOV-1Activator interaction domain-containing protein 2prostate tumor overexpressed 1

no direct mechanism for drug action against PTOV1 described to date; potential targeting would involve inhibition of its role as a transcriptional/coregulatory or RNA-binding factor